| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Paradigm Genetics, Inc. |
| 104 Alexander Drive, Research Triangle Park, NC 27709 * (919) 425-3000 |
| Business Description | The company is industrializing the process of determining gene function to generate information that will enable us to develop novel products in four major sectors of the global economy: crop production, nutrition, human health and industrial products. |
|
Filing Information Not yet | |||
| To Trade As | PDGM (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/18/00 |
| Domestic Shares Filed | 5,000,000 | Filing Range | $7.00 - $8.00 |
| Foreign Shares Filed | 0 | Offering Amount | $37,500,000 |
| Company Shares | 5,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| J.P. Morgan & Co. | Co-manager | (212) 648-0517 |
| Pacific Growth Equities | Co-manager | (415) 274-6800 |
| Stephens Inc. | Co-manager | (501) 377-2130 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 0.000 | 0.871 | 2.197 | - | - |
| Income from Oper. | - | - | -0.220 | -4.300 | -10.111 | - | - |
| Net Income | - | - | -0.220 | -4.290 | -10.487 | - | - |
| E.P.S | - | - | -0.190 | -1.140 | -2.480 | - | - |
| Revenue Growth (%) | - | - | - | 152.364 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -4.43 | - | - | ||||
| Cash Flow - Inv. | -7.59 | - | - | ||||
| Cash Flow - Fin. | 11.51 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 29.23 | Current Assets | 20.37 | Current Ratio | 2.26 |
| Total Liab. | 17.05 | Current Liab. | 9.01 | Debt Ratio | 58.35% |
| Total Equity | 12.17 | Working Cap. | 11.36 | Debt to Equity Ratio | 1.40 |
| Cash | 0.47 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development and general corporate purposes including possible acquisition of or investment in complementary businesses, products or technologies.. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Bank's Law Firm | Morgan, Lewis & Bockius |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Polaris Venture Funds | 21.40 | |
| Innotech Investments Limited | 20.50 | |
| Intersouth Partners | 19.20 | |
| The Burrill AgBio Capital Fund L.P. | 9.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||